EUVIMEDEUVIMED entdecken
Open Access

Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma

Rebecca Waters, Matheus Sewastjanow-Silva iD, Kohei Yamashita, Ahmed Abdelhakeem iD, Kenneth K Iwata iD, Diarmuid Moran, Dina Elsouda, Abraham Guerrero, Melissa Pizzi, Ernesto Rosa Vicentini iD, Namita Shanbhag, Anh Ta und 2 weitere

JCO Precision Oncology · 2024-05 · (8)

DOI: 10.1200/po.23.00543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-05. Verfasst von Rebecca Waters und 13 weiteren Autor:innen. Beteiligte Einrichtung: MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Esophagogastric Junction, Claudins. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Claudin 18 isoform 2 (CLDN18.2) is an emerging biomarker and therapeutic target in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. This study aimed to obtain deeper understanding of CLDN18.2 positivity patterns, prognostic implications, and associations with various demographic, clinical, and molecular characteristics in G/GEJ adenocarcinoma. METHODS Archived tumor tissue samples from 304 patients with G/GEJ adenocarcinoma in the United States were assessed for CLDN18.2 positivity by immunohistochemistry. CLDN18.2 positivity was defined as ≥50% or ≥75% of tumor cells with CLDN18 staining intensity ≥2+. CLDN18.2 positivity patterns were analyzed for association with prognosis and clinicopathologic/demographic characteristics. Where possible, CLDN18.2 positivity was analyzed for matched tissue samples to assess concordance between primary and metastatic tumors and concordance before and after chemotherapy. RESULTS The overall prevalence of CLDN18.2-positive tumors (with ≥75% cutoff) was 44.4% (n = 135 of 304). CLDN18.2-positive tumors had a prevalence of 51.4% (n = 91 of 177) in gastric and 34.6% (n = 44 of 127) in GEJ adenocarcinoma. With a ≥50% cutoff, the prevalence of CLDN18.2-positive tumors was 64.4% (n = 114 of 177) in gastric adenocarcinoma and 44.9% (n = 57 of 127) in GEJ adenocarcinoma. There was no association between overall survival and CLDN18.2 positivity using either threshold. Statistically significant associations were noted between CLDN18.2 positivity and sex, histologic type of G/GEJ adenocarcinoma, and adenocarcinoma subtype (≥75% cutoff), and metastasis site and tumor grade (≥50% cutoff). The overall concordance of CLDN18.2 positivity (≥75% cutoff) was 73% (27 of 37) for matched primary versus metastatic tumor samples and 74% (29 of 39) for matched samples before and after chemotherapy. CONCLUSION This study demonstrated that CLDN18.2 positivity did not correlate with survival in G/GEJ adenocarcinoma, consistent with published data. On the basis of matched sample analysis, CLDN18.2 appears to demonstrate >70% concordance as a biomarker. Observed correlations with certain patient/tumor characteristics warrant further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaEsophagogastric JunctionClaudinsEsophageal NeoplasmsHumansMaleFemaleMiddle AgedAgedPrognosisRetrospective StudiesProtein IsoformsAdultAged, 80 and overPrevalence

Substanzen

ClaudinsCLDN18 protein, humanProtein Isoforms

Autor:innen und Institutionen

  • MD Anderson Cancer Center, Houston, TX.
  • Astellas Pharma, Inc, Northbrook, IL.

ORCID-Profile: Matheus Sewastjanow-Silva, Ahmed Abdelhakeem, Kenneth K Iwata, Ernesto Rosa Vicentini, Deyali Chatterjee, Jaffer A Ajani

Zitieren

APA

Waters, R., Sewastjanow-Silva, M., Yamashita, K., Abdelhakeem, A., Iwata, K. K., Moran, D., Elsouda, D., Guerrero, A., Pizzi, M., Vicentini, E. R., Shanbhag, N., Ta, A., Chatterjee, D., & Ajani, J. A. (2024). Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma. JCO Precision Oncology. https://doi.org/10.1200/po.23.00543

Vancouver

Waters R, Sewastjanow-Silva M, Yamashita K, Abdelhakeem A, Iwata KK, Moran D, et al. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma. JCO Precision Oncology. 2024. doi:10.1200/po.23.00543

BibTeX
@article{Waters2024,
  author = {Waters, Rebecca and Sewastjanow-Silva, Matheus and Yamashita, Kohei and Abdelhakeem, Ahmed and Iwata, Kenneth K and Moran, Diarmuid and Elsouda, Dina and Guerrero, Abraham and Pizzi, Melissa and Vicentini, Ernesto Rosa and Shanbhag, Namita and Ta, Anh and Chatterjee, Deyali and Ajani, Jaffer A},
  title = {Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma},
  journal = {JCO Precision Oncology},
  year = {2024},
  number = {8},
  doi = {10.1200/po.23.00543}
}
Kostenlos starten →